Imanishi Naoko
   Department   University Hospital  General Thoracic Surgery, Clinical Departments
Article types case reports
Language English
Peer review Peer reviewed
Title Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report.
Journal Formal name:Case reports in oncology
Abbreviation:Case Rep Oncol
ISSN code:/16626575
Domestic / ForeginForegin
Volume, Issue, Page 9(3),565-567頁
Author and coauthor Kuwata Taiji, Yoneda Kazue, Kobayashi Kenichi, Oyama Rintarou, Matumiya Hiroki, Shinohara Shuichi, Takenaka Masaru, Oka Soichi, Chikaishi Yasuhiro, Imanishi Naoko, Kuroda Koji, Tanaka Fumihiro
Publication date 2016/09
Summary Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) may achieve long-term survival in selected cases with advanced non-small cell lung cancer harboring activating mutations in the EGFR gene, but a cured case has not been reported yet. Here, we present the first case of EGFR-mutated lung adenocarcinoma cured with an EGFR-TKI, as the 75-year-old Japanese man has achieved complete response with gefitinib treatment and has survived without tumor 10 years after termination of gefitinib treatment.
DOI 10.1159/000449371
PMID 27790122